Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON is fully enrolled; GRAND CANYON is currently enrolling.
Epistemonikos ID: e1049118ced652ee2f597e6d474e070353b8609e
First added on: May 10, 2024